Hostname: page-component-cd9895bd7-fscjk Total loading time: 0 Render date: 2024-12-22T18:48:39.063Z Has data issue: false hasContentIssue false
  • English
  • Français

Famotidine: a supplemental drug for the treatment of schizophrenia

Published online by Cambridge University Press:  16 April 2020

PN Dannon ,
E Lepkifker ,
I Iancu ,
R Ziv ,
N Horesh  and
M Kotler
PN Dannon
Affiliation:
Division of Psychiatry, Chaim Sheba Medical Center, Tel-Hashomer, 52621, Israel
E Lepkifker*
Affiliation:
Division of Psychiatry, Chaim Sheba Medical Center, Tel-Hashomer, 52621, Israel
I Iancu
Affiliation:
Division of Psychiatry, Chaim Sheba Medical Center, Tel-Hashomer, 52621, Israel
R Ziv
Affiliation:
Division of Psychiatry, Chaim Sheba Medical Center, Tel-Hashomer, 52621, Israel
N Horesh
Affiliation:
Division of Psychiatry, Chaim Sheba Medical Center, Tel-Hashomer, 52621, Israel
*
*Correspondence and reprints.
Get access

Summary

In an open-label study, famotidine was added to the regular neuroleptic regimen of 11 schizophrenic patients for 4 weeks. Each patient was scored weekly with SAPS, SANS, CGI and HAM-D-17 scales. The results suggest that famotidine is indeed effective as an adjunctive drug to neuroleptics in the treatment of schizophrenia.

Keywords

famotidineH2-receptor antagonistsschizophrenianeuroleptics
Type
Rapid Communication
Information
European Psychiatry , Volume 12 , Issue 5 , 1997 , pp. 263 - 264
Copyright
Copyright © European Psychiatric Association 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Carpenter, W., Buchanan, R. Schizophrenia (A Review). N Engl J Med 1994; 330: 681–688CrossRefGoogle Scholar
Chermos, AN. Pharmacodynamics of famotidine in humans. Am J Med 84suppl 4B1986 3–7CrossRefGoogle Scholar
Deutsch, SI, Rosse, RB, Kendrick, KA, Fay-McCarthy, M, et al.. Famotidine adjunctive pharmacotherapy for schizophrenia: preliminary data. Clin Neuropharmacol 1993; 16: 518–52410.1097/00002826-199312000-00005CrossRefGoogle ScholarPubMed
Hough, LB. Cellular localization and possible functions for brain histamine: recent progress. Prog Neurohiol 1988; 30: 469–50510.1016/0301-0082(88)90032-9CrossRefGoogle ScholarPubMed
Kaminsky, R, Moriarty, TM, Bodine, J, Wolf, DE, Davidson, M. Effect of famotidine on deficit symptoms of schizophrenia. Lancet 1989; 335: 1351–135210.1016/0140-6736(90)91237-5CrossRefGoogle Scholar
Rifkin, A. Pharmacological strategies in the treatment of schizophrenia. Psych Clin of North America 1993; 16: 351–362CrossRefGoogle Scholar
Rosse, RB, Kendrick, K, Fay-McCarthy, M, Prell, GD, et al.. An open-label study of the therapeutic efficacy of high-dose famotidine adjuvant pharmacotherapy in schizophrenia: preliminary evidence for treatment efficacy. Clin Neuropharmacol 1996; 19: 341–34810.1097/00002826-199619040-00007CrossRefGoogle ScholarPubMed
White, JM, Rumbold, CR. Behavioral effects of histamine and its antagonists: a review. Psychopharmacology 1988; 95: 1–410.1007/BF00212757CrossRefGoogle ScholarPubMed
Yoshimolo, K, Saima, S, Echizen, H, Nakamura, Y, et al.. Famotidine-associated CNS reactions and plasma and CS drug concentrations in neurosurgical patients with renal failure. Clin Pharmacol Ther 1994; 55: 693–s70010.1038/clpt.1994.86CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.